Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more
Ondine Biomedical Inc - Asset Resilience Ratio
Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2007)
This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.88 Million | 39.85% |
| Total Liquid Assets | GBX1.88 Million | 39.85% |
Asset Resilience Insights
- Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio
Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ |
Biotechnology | 9.01% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 73.50% |
|
Jacobio Pharmaceuticals Group Co. Ltd.
PINK:JBPHF |
Biotechnology | 6.22% |
|
genOway Société anonyme
F:JEH |
Biotechnology | 0.00% |
|
Jasper Therapeutics Inc
NASDAQ:JSPR |
Biotechnology | 53.37% |
|
ToolGen Inc.
KQ:199800 |
Biotechnology | 29.98% |
|
JW (Cayman) Therapeutics Co. Ltd
PINK:JWCTF |
Biotechnology | 0.31% |
|
Vaxcell-Bio Therapeutics Co. Ltd
KQ:323990 |
Biotechnology | 32.97% |
Annual Asset Resilience Ratio for Ondine Biomedical Inc (2006–2007)
The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2007-12-31 | 43.12% | GBX5.61 Million | GBX13.00 Million | -15.66pp |
| 2006-12-31 | 58.78% | GBX10.85 Million | GBX18.46 Million | -- |